AGTR1 and cardiovascular disorder: Therefore, future studies to identify ligands that preserve the ability to activate β-arrestin-2-biased AT1R signalling but are devoid of Gq and β arrestin-1 signalling may result in more beneficial drug candidates for treating cardiovascular diseases.